Surrozen (SRZN) Stock Price, News & Analysis

Company Overview

Surrozen, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation.

The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues. Its development programs have focused on potential treatments for diseases involving the liver, gastrointestinal system and other tissues where impaired regeneration contributes to disease.

Surrozen’s pipeline has included SZN-043, an investigational Wnt pathway agonist being developed for liver-related conditions, and SZN-1326, an investigational program aimed at gastrointestinal diseases such as ulcerative colitis. The company’s programs remain subject to clinical testing and regulatory review, and their safety and effectiveness have not been established.

Key Stats

• Today's Range: $31.69 to $33.75
• 50-Day Range: $16.16 to $33.68
• 52-Week Range: $12.12 to $37.83
• Volume: 157,137 shs
• Average Volume: 322,716 shs
• Market Capitalization: $370.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $61.75
• Consensus Rating: Moderate Buy

Surrozen Stock Analysis - MarketRank™

Surrozen scored higher than 49% of companies evaluated by MarketBeat, and ranked 567th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Surrozen has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Surrozen has a consensus price target of $61.75, representing about 93.7% upside from its current price of $31.88.

Amount of Analyst Coverage

Surrozen has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Surrozen are expected to decrease in the coming year, from ($1.01) to ($4.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Surrozen is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Surrozen is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

40.82% of the float of Surrozen has been sold short.

Short Interest Ratio / Days to Cover

Surrozen has a short interest ratio ("days to cover") of 8.51.

Change versus previous month

Short interest in Surrozen has recently increased by 3.31%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Surrozen does not currently pay a dividend.

Dividend Growth

Surrozen does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.14

News Sentiment

Surrozen has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Surrozen this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Surrozen insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.74% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/09/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SRZN
• CIK: 1824893
• Web: www.surrozen.com
• Phone: 650-489-9000
• Fax: N/A
• Employees: 44
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Surrozen: $61.75
• High Price Target: $80.00
• Low Price Target: $51.00
• Potential Upside/Downside: +93.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($43.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$242.03 million
• Net Margins: -2,885.33%
• Pretax Margin: -2,885.33%
• Return on Equity: N/A
• Return on Assets: -112.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.14
• Quick Ratio: 12.14

Sales & Book Value

• Annual Sales: $10.53 million
• Price / Sales: 35.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($19.21) per share
• Price / Book: -1.66

Miscellaneous

• Outstanding Shares: 11,610,000
• Free Float: 7,925,000
• Market Cap: $370.13 million
• Optionable: Optionable
• Beta: 0.51